-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lysergic Acid Diethylamide in Anxiety Disorders
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lysergic Acid Diethylamide in Anxiety Disorders report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lysergic Acid Diethylamide in Anxiety Disorders Drug Details: Lysergic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Delgocitinib in Hand Dermatitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Delgocitinib in Hand Dermatitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Delgocitinib in Hand Dermatitis Drug Details: Delgocitinib (Corectim) acts as anti-allergic agent....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pravibismane in Diabetic Foot Infection (DFI)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pravibismane in Diabetic Foot Infection (DFI) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pravibismane in Diabetic Foot Infection (DFI) Drug Details: Pravibismane (MBN-101)...
-
Company Insights
Innovation and Patenting activity of Mind Medicine MindMed Inc Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Mind Medicine MindMed Inc Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – QNIV in Influenza A Virus, H1N1 Subtype Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - QNIV in Influenza A Virus, H1N1 Subtype Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. QNIV in Influenza A Virus, H1N1 Subtype Infections...
-
Product Insights
NewCluster Headache Syndrome (Cluster Headache) – Drugs In Development, 2024
Empower your strategies with our Cluster Headache Syndrome (Cluster Headache) – Drugs In Development, 2024 report and make more profitable business decisions. Cluster headache is pain that occurs along one side of the head. It frequently occurs around, behind, or above the eye. Symptoms include burning, sharp, steady pain; red eyes; runny nose; excessive tearing; and flushed face. Risk factors include age and gender. Treatment includes anti-inflammatory (steroid) medicines and triptans. The Cluster Headache Syndrome (Cluster Headache) drugs in development market...
-
Product Insights
NewSocial Anxiety Disorder (SAD/Social Phobia) – Drugs In Development, 2024
Empower your strategies with our Social Anxiety Disorder (SAD/Social Phobia) – Drugs In Development, 2024 report and make more profitable business decisions. Social anxiety disorder (SAD), also known as social phobia, is an anxiety disorder characterized by sentiments of fear and anxiety in social situations, causing considerable distress and impairing ability to function in at least some aspects of daily life. These fears can be triggered by perceived or actual scrutiny from others. The Social Anxiety Disorder (SAD/Social Phobia) drugs in...
-
Product Insights
NewGeneralized Anxiety Disorder (GAD) – Drugs In Development, 2024
Empower your strategies with our Generalized Anxiety Disorder (GAD) – Drugs In Development, 2024 report and make more profitable business decisions. Generalized anxiety disorder is a mental health disorder that produces fear, worry, and a constant feeling of being overwhelmed. It is characterized by excessive, persistent, and unrealistic worry about everyday things. Individuals with GAD typically experience heightened anxiety and apprehension, anticipating negative outcomes in everyday situations. Physical symptoms may include restlessness, muscle tension, fatigue, and difficulty concentrating. Unlike specific phobias...
-
Product Insights
NewAttention Deficit Hyperactivity Disorder (ADHD) – Drugs In Development, 2024
Empower your strategies with our Attention Deficit Hyperactivity Disorder (ADHD) – Drugs In Development, 2024 report and make more profitable business decisions. Attention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity, and impulsiveness. Symptoms of ADHD include disorganized work habits, procrastination, and inability to sustain attention on tasks or activities. Treatment includes analeptics. The Attention Deficit Hyperactivity Disorder (ADHD) drugs in development market research report provide comprehensive information on the therapeutics under development for Attention...
-
Product Insights
NewAutism Spectrum Disorder (ASD) – Drugs In Development, 2024
Empower your strategies with our Autism Spectrum Disorder (ASD) – Drugs In Development, 2024 report and make more profitable business decisions. Autism Spectrum Disorder (ASD) is a neurodevelopmental condition characterized by challenges in social interaction, communication, and repetitive behaviors. Symptoms range from mild to severe, forming a spectrum. Individuals with ASD may have difficulties in understanding social cues, expressing emotions, and engaging in reciprocal conversations. Sensory sensitivities are common, affecting responses to stimuli. Early intervention and tailored support can enhance communication...